144 ·Filed Jun 10, 2026

ANAB

ANAPTYSBIO, INC
BEARISH
Impact 5/10
Horizonweeks Processed3mo ago SEC0001950047-26-005897
Form 144 — notice of proposed sale of securities
Actionable Insight ▼ Bearish

The repeated insider selling by a key officer is a bearish signal, though the stock has shown resilience. Monitor for additional 144 filings or Form 4 submissions indicating further sales. Consider the pattern as a potential headwind to near-term price appreciation.

DirectionBearish
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d
ANAB ▲ +4.72% at T+60d
SHORT call ✗ call lost -4.72% · α vs SPY -0.32% · entry $54.24 → $56.80
Entry anchored
Jun 10, 03:59 PM ET
via exchange tick
T+1d
+3.37%
call -3.37% · α -2.83%
$56.07
settled 4mo ago
T+5d
+4.66%
call -4.66% · α -4.23%
$56.77
settled 4mo ago
T+20d
+22.77%
call -22.77% · α -20.88%
$66.59
settled 3mo ago
T+60d
+4.72%
call -4.72% · α -0.32%
$56.80
settled 28d ago

Price Chart

Loading chart...

Executive Summary

Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 10, 2026, indicating intent to sell 20,000 shares (~$1.05M). This is part of a heavy selling pattern with over 250,000 shares sold in the past month, representing a significant insider distribution. The sustained selling by a key officer raises caution despite strong analyst consensus.

Key Facts

  • Officer Dennis Mulroy intends to sell 20,000 shares valued at ~$1,046,560.
  • Mulroy has sold over 250,000 shares in the past month (since May 15, 2026), totaling roughly $13M.
  • The 144 filing is for shares acquired via stock option exercise.
  • AnaptysBio has a market cap of $1.5B and 94% analyst bullish rating.

Financial Impact

Officer Dennis Mulroy proposes to sell 20,000 shares worth ~$1.05M, part of a selling spree totaling over 250,000 shares valued at ~$13M in the past month (May 15 – June 10, 2026).

dilutioninsider selling volume

Risk Factors

  • Continued insider selling could signal management's lack of confidence ahead of upcoming catalysts or earnings.
  • The selling volume may create technical overhang, especially if open-market sales persist.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005897
Document: 0001950047-26-005897-index.html0001950047-26-005897
Document: 0001950047-26-005897.txt0001950047-26-005897
24 reports for ANAB
Performance horizon
71% Hit rate 12 of 17 directional calls best @ T+60▲ +41.26%Mar 3, 2026
Filters
Rows
Reports for ANAB — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$56.02 $53.87▼ −3.84%▼ −2.09%$48.53 (−13.37%)
Jun 29, 2026
13w ago
144
BEARISH ★ 6/10
$67.50 $53.61▲ +20.58%▲ +19.55%$48.53 (+28.10%)
Jun 29, 2026
13w ago
DEFA14A
NEUTRAL ★ 2/10
$67.50 $53.61▼ −20.58%▼ −19.55%$48.53 (−28.10%)
Jun 26, 2026
14w ago
144
BEARISH ★ 6/10
$65.97 $54.15▲ +17.92%▲ +17.64%$48.53 (+26.44%)
Jun 22, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$59.43 $50.29▼ −15.38%▼ −16.54%$48.53 (−18.34%)
Jun 17, 2026
15w ago
144
BEARISH ★ 5/10
$57.51 $54.15▲ +5.84%▲ +6.38%$48.53 (+15.61%)
Jun 15, 2026
15w ago
144
BEARISH ★ 6/10
$57.61 $62.51▼ −8.51%▼ −8.31%$48.53 (+15.76%)
Jun 11, 2026
16w ago
144
BEARISH ★ 6/10
$56.07 $66.39▼ −18.41%▼ −16.63%$48.53 (+13.45%)
Jun 10, 2026
16w ago
144
BEARISH ★ 5/10
$54.24 $66.59▼ −22.77%▼ −20.88%$48.53 (+10.53%)
Jun 8, 2026
16w ago
144
BEARISH ★ 5/10
$51.63 $67.33▼ −30.40%▼ −28.95%$48.53 (+6.00%)
Showing 10 of 24

US Market Status

Market Closed — Opens Mon (38h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access